National Institute of Advanced Industrial Science and Technology

The University of Tokyo

Chugai Seiyaku Kabushiki Kaisha

Yuriko Uehara

Hiroyuki Aburatani

Toru Imamura

Syuichi Oka

Masashi Suzuki

Masahiro Asada

Akiko Kuramochi

Shinichi Funahashi

Miho Kimura

Kaori Motomura

Junko Oki

Using betaKlotho or a substance that increases or inhibits betaKlotho activity as an agent for controlling the activity of FGF21 mediated by an FGF receptor, the present invention provides a pharmaceutical composition comprising such betaKlotho or such substance as an active ingredient, particularly, a pharmaceutical composition for anti-metabolic syndrome, and further particularly, a pharmaceutical composition for therapeutic or preventive use associated with the control of blood glucose level. In addition, the present invention provides a screening system for each of a substance that enhances or suppresses betaKlotho activity, an FGF21-like active substance, and a betaKlotho-like active substance, which uses a cell system that has expressed an FGF receptor and/or betaKlotho on the surface thereof.

Method for screening a test substance for activating a receptor associated with FGF 21 activity

Growing community of inventors

Ibaraki, Japan

Yuriko Uehara